When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

NDAQ:VKTX) Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

What new medicines are poised to take the leap from breakthrough to approval in 2025? Here’s what to expect this year.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

It is also marketed under the brand name Mounjaro for type 2 diabetes. GLP-1 RAs, including tirzepatide and Novo Nordisk’s semaglutide (marketed as Wegovy and Ozempic), have seen rapid adoption due to ...

In contrast, HS-10535 is a small molecule drug, which ... as well as sibling medicines like its drug Wegovy for treating obesity, if Merck's weight loss candidate is easier to make, it could ...

In the brain, the enzyme ABHD6 degrades a key endocannabinoid molecule known as 2-arachidonoylglycerol (2-AG). Stephanie Fulton, a CRCHUM researcher and professor at Université de Montréal, with David ...